Quantcast

Latest Rhinitis Stories

2010-11-18 04:00:00

OXFORD, England, November 18, 2010 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced successful clinical results from a phase II study of its T-cell vaccine targeting house dust mite allergy. The study met each of the safety and efficacy endpoints, with the optimal treatment regimen achieving a major reduction in patients' reactions to house dust mite allergens. These results build on four earlier successful phase II studies of...

2010-11-08 16:00:00

European Phase 2 Clinical Trial Evaluating WF10 as a Treatment for Severe Allergic Rhinitis Meets its Primary Endpoint MISSISSAUGA, ON, Nov. 8 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies and on the development of its immune modulating drug candidate WF10, today announced that its European...

2010-10-07 07:00:00

SAN DIEGO and SEATTLE, Oct. 7 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) candidates for the treatment of cancer, respiratory and inflammatory diseases, announced today results from its randomized, placebo controlled clinical trial evaluating VTX-1463 for the treatment of allergic rhinitis. The results demonstrated that VTX-1463 significantly improved allergy symptoms based on Total Nasal Symptom...

2010-10-06 06:30:00

IRVINE, Calif., Oct. 6 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced positive preliminary results from a Phase 1/2 clinical study of bepotastine besilate nasal spray conducted in Canada for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies. The findings demonstrated two of the three bepotastine besilate concentrations tested were effective in relieving patients' nasal...

2010-09-30 03:58:00

OXFORD, England, September 30, 2010 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has further advanced the clinical development of three of its leading T-cell allergy vaccines.' In recent weeks, Circassia has initiated phase II clinical testing of its grass allergy (hayfever) therapy, begun the final stage of phase II testing with its ragweed allergy treatment and progressed phase III development plans for its cat allergy...

2010-09-06 13:55:00

ANTONY, France, September 6, 2010 /PRNewswire-FirstCall/ -- Stallergenes S.A. has announced today the signing of exclusive partnership agreements with Shionogi & Co., Ltd. for two sublingual allergen immunotherapy tablet products resulting from the Stalair(R) program: Actair(R) house dust mite tablets and Japanese cedar pollen tablets. With 32 million respiratory allergy sufferers, there is a strong - and as yet unmet - demand for treatment in Japan, where sublingual allergen...

7ab7459b9a97d66fb5a5c3b446e3de371
2010-08-13 09:10:00

New evidence linking the use of acetaminophen to development of asthma and eczema suggests that even monthly use of the drug in adolescents may more than double risk of asthma in adolescents compared to those who used none at all; yearly use was associated with a 50 percent increase in the risk of asthma. The research results will be published online on the American Thoracic Society's Web site ahead of the print edition of the American Journal of Respiratory and Critical Care Medicine. "This...

2010-07-28 09:45:00

HORSHAM, Pa., July 28 /PRNewswire/ -- Teva Respiratory today announced positive results from a Phase III trial evaluating the efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol in the treatment of seasonal allergic rhinitis (SAR). The study met all efficacy endpoints, demonstrating a statistically significant benefit as compared to placebo. Furthermore, the safety profile of BDP HFA Nasal Aerosol was similar to placebo. "The outcomes of the...

2010-07-14 06:30:00

IRVINE, Calif., July 14 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced it has initiated a Phase 1/2 clinical study of bepotastine besilate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies. The randomized, placebo-controlled, parallel-group study will evaluate the safety and efficacy of three concentrations of bepotastine besilate, dosed twice daily, in an...

2010-07-09 15:39:00

AUSTIN, Texas, July 9 /PRNewswire/ -- Lake levels are higher and the normally brown Austin roadside is green and lush, but for allergy sufferers summer showers can increase their exposure to allergenic mold spores. Molds can be found inside and outside the home. Along with pollens from trees, grasses, and weeds, molds are an important trigger of allergic rhinitis, affecting nearly 40 million Americans, according to the American Academy of Allergy, Asthma & Immunology (AAAAI). "Mold...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related